Treatment of sialorrhea with glycopyrrolate: A double-blind, dose-ranging study.
OBJECTIVE
To determine the safety and efficacy of glycopyrrolate in the treatment of developmentally disabled children with sialorrhea.


METHODS
Placebo-controlled, double-blind, crossover dose-ranging study.


METHODS
Outpatient facilities in 2 pediatric hospitals.


METHODS
Thirty-nine children with both developmental disabilities and excessive and bothersome sialorrhea.


METHODS
Parent and investigator evaluation of change in sialorrhea and adverse effects.


RESULTS
Glycopyrrolate in doses of 0.10 mg/kg per dose is effective at controlling sialorrhea. Even at low doses, 20% of children may exhibit adverse effects severe enough to require discontinuation.


CONCLUSIONS
Glycopyrrolate is effective in the control of excessive sialorrhea in children with developmental disabilities. Approximately 20% of children given glycopyrrolate may experience substantial adverse effects, enough to require discontinuation of medication. Arch Pediatr Adolesc Med. 2000;154:1214-1218.
Mier
R J
RJ
Shriners Hospital for Children, 1900 Richmond Rd, Lexington, KY 40502, USA. rjmier@aol.com
Bachrach
S J
SJ
Lakin
R C
RC
Barker
T
T
Childs
J
J
Moran
M
M
D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D018592:Cross-Over Studies; D002658:Developmental Disabilities / Q000150:complications*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D006024:Glycopyrrolate / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D018727:Muscarinic Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D012798:Sialorrhea / Q000150:complications* / Q000188:drug therapy*
D018727:Muscarinic Antagonists; D006024:Glycopyrrolate